Literature DB >> 18510697

Foxp3 expression on normal and leukemic CD4+CD25+ T cells implicated in human T-cell leukemia virus type-1 is inconsistent with Treg cells.

Masaki Abe1, Kinya Uchihashi, Tsuruda Kazuto, Akemi Osaka, Katsunori Yanagihara, Kunihiro Tsukasaki, Hiroo Hasegawa, Yasuaki Yamada, Shimeru Kamihira.   

Abstract

Foxp3 is a master gene of Treg cells, a novel subset of CD4(+) T cells primarily expressing CD25. We describe here different features in Foxp3 expression profile between normal and leukemic CD4(+)CD25(+) T cells, using peripheral blood samples from healthy controls (HCs), human T-cell leukemia virus type-1 (HTLV-1)-infected asymptomatic carriers (ACs), patients with adult T-cell leukemia (ATL), and various hematopoietic cell lines. The majority of CD4(+)CD25(+) T cells in HCs were positive for Foxp3, but not all CD4(+)CD25(+) T cells in ACs were positive, indicating that Foxp3 expression is not always linked to CD25 expression in normal T cells. Leukemic (ATL) T cells constitutively expressing CD25 were characteristic of heterogeneous Foxp3 expression, such as intra- and inter-case heterogeneity in intensity, inconsistency with CD25 expression, and a discrepancy in the mRNA and its protein expression. Surprisingly, a discernible amount of Foxp3 mRNA was detectable even in most cell lines without CD25 expression, a small fraction of which was positive for the Foxp3 proteins. The subcellular localization of Foxp3 in HTLV-1-infected cell lines was mainly cytoplasmic, different from that of primary ATL cells. These findings indicate that Foxp3 has two facets: essential Treg identity and molecular mimicry secondary to tumorigenesis. Conclusively, Foxp3 in normal T cells, but not mRNA, is basically potent at discriminating a subset of Treg cells from CD25(+) T-cell populations, whereas the modulation of Foxp3 expression in leukemic T cells could be implicated in oncogenesis and has a potentially useful clinical role.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18510697     DOI: 10.1111/j.1600-0609.2008.01105.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  16 in total

1.  Heterogeneity in clonal nature in the smoldering subtype of adult T-cell leukemia: continuity from carrier status to smoldering ATL.

Authors:  Shimeru Kamihira; Masako Iwanaga; Yuko Doi; Daisuke Sasaki; Sayaka Mori; Kazuto Tsurda; Kazuhiro Nagai; Naoki Uno; Hiroo Hasegawa; Katsunori Yanagihara; Yoshitomo Morinaga; Kunihiro Tsukasaki; Hiroaki Taniguchi
Journal:  Int J Hematol       Date:  2012-03-28       Impact factor: 2.490

2.  Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases.

Authors:  Shuko Murakami; Yasumitsu Nishimura; Megumi Maeda; Naoko Kumagai; Hiroaki Hayashi; Ying Chen; Masayasu Kusaka; Takumi Kishimoto; Takemi Otsuki
Journal:  Environ Health Prev Med       Date:  2009-03-18       Impact factor: 3.674

Review 3.  Are increased Foxp3+ regulatory T cells responsible for immunosuppression during HTLV-1 infection? Case reports and review of the literature.

Authors:  Nicolas Barros; Fernando Woll; Luis Watanabe; Martin Montes
Journal:  BMJ Case Rep       Date:  2012-11-27

4.  Induction of immune tolerance in asthmatic mice by vaccination with DNA encoding an allergen-cytotoxic T lymphocyte-associated antigen 4 combination.

Authors:  Fang Zhang; Gang Huang; Bo Hu; Yong Song; Yi Shi
Journal:  Clin Vaccine Immunol       Date:  2011-02-23

5.  Adult T-cell lymphoma/leukaemia with haematemesis as a prodromal manifestation.

Authors:  Fariba Binesh; Mohamad Reza Mirjalili; Hasanali Vahedian; Hamidreza Bashiri
Journal:  BMJ Case Rep       Date:  2012-11-28

6.  Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells.

Authors:  Frederic Toulza; Kisato Nosaka; Yuetsu Tanaka; Tiziana Schioppa; Frances Balkwill; Graham P Taylor; Charles R M Bangham
Journal:  J Immunol       Date:  2010-06-04       Impact factor: 5.422

7.  HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+ T cells in virus-infected individuals.

Authors:  Yorifumi Satou; Atae Utsunomiya; Junko Tanabe; Masanori Nakagawa; Kisato Nosaka; Masao Matsuoka
Journal:  Retrovirology       Date:  2012-05-30       Impact factor: 4.602

8.  MicroRNA miR-146a and further oncogenesis-related cellular microRNAs are dysregulated in HTLV-1-transformed T lymphocytes.

Authors:  Klemens Pichler; Grit Schneider; Ralph Grassmann
Journal:  Retrovirology       Date:  2008-11-12       Impact factor: 4.602

9.  Molecular and Cellular Mechanism of Leukemogenesis of ATL: Emergent Evidence of a Significant Role for HBZ in HTLV-1-Induced Pathogenesis.

Authors:  Yorifumi Satou; Masao Matsuoka
Journal:  Leuk Res Treatment       Date:  2011-11-24

10.  Is There a Role for HTLV-1-Specific CTL in Adult T-Cell Leukemia/Lymphoma?

Authors:  Aileen G Rowan; Charles R M Bangham
Journal:  Leuk Res Treatment       Date:  2011-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.